Clinical Trial

Development of Healthcare Transition for Patients With Congenital Adrenal Hyperplasia

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to implement and evaluate the feasibility and acceptability of a structured healthcare transition program for adolescents and young adults with congenital adrenal hyperplasia (CAH). The study will also examine preliminary effects of the program on transition readiness, disease-specific self-management knowledge, emergency preparedness, continuity of endocrine care, and health-related quality of life as participants transition from pediatric to adult healthcare services.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-05-20; most recent amendment 2026-07-07.
Trial Details
NCT Number NCT07611786
Lead Sponsor University of Alabama at Birmingham
Collaborators: Neurocrine Biosciences
Conditions Congenital Adrenal Hyperplasia
Enrollment 40 participants
Start Date 2026-07
Primary Completion 2028-07 (estimated)
Study Completion 2029-07 (estimated)
Updated on ClinicalTrials.gov 2026-07-08